Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Accro Raises $50 Million for Regulated Cell Death Drug Candidates

publication date: Jan 5, 2022

Accro Bioscience (Suzhou) raised more than $50 million in an oversubscribed Series B round to develop products based on the molecular mechanism of regulated cell death. Its portfolio of China Class 1.1 candidates include products for inflammatory, autoimmune and cancer indications. The company's research focuses on necroptosis, pyroptosis and ferroptosis, which are associated with major human diseases. The B round was led by Hongtai Aplus. Also participating were South China Venture apital, Shenzhen Capital Group and Suzhou Oriza Holdings.  More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here